Clinical Features Associated With Restless Legs Syndrome. (Clin-RLS)
Status
Conditions
Details and patient eligibility
About
Restless legs syndrome (RLS) is a chronic neurological disorder characterized by an urge to move the legs at night when at rest. RLS can lead to a sleep deprivation, increased falling risk, daytime sleepiness, depression and decreased quality of life. Dopamine agonists, alpha-2-delta ligands and opiates are key medications for RLS. The natural course of RLS is very heterogeneous with a risk of increasing the severity of symptoms over the years despite the use of drugs and recommended dosages. Many comorbidities can make RLS worse. Augmentation syndrome is the main complication of dopamine agonists. However, only a few studies have addressed the clinical, biological and pharmacological factors associated with the evolution of the severity of RLS. The objective of this study is to assess the evolution of RLS symptoms severity as function of RLS phenotype, comorbidities and RLS medication, in large cohort of members of the French RLS association and other European RLS association.
Full description
In this study, the investigators want to study the clinical course of RLS in a population of RLS patients who are members of the RLS patient association, taking into account clinical and biological factors as well as the treatments taken for RLS.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Adults subjects
- Restless legs syndrome diagnosis
- Member of the restless legs syndrome association
- French speaking
- Able to understand the study
- Signed written informed consent
- Affiliated to social security
Exclusion criteria
- Vulnerable subject : subject deprived of liberty or protected by law (trusteeship, legal guardianship)
Trial contacts and locations
Loading...
Central trial contact
Yves DAUVILLIERS, MD PhD; Sofiene Chenini, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal